SPAC

Antibody biotech Abpro taps SPAC to get back on Nasdaq track 5 years after axed IPO
Antibody biotech Abpro taps SPAC to get back on Nasdaq track 5 years after axed IPO
Fierce Biotech
AbPro
IPOs
SPAC
NASDAQ
Flag link:
Device company HDL Therapeutics eyes public listing in $480m SPAC deal
Device company HDL Therapeutics eyes public listing in $480m SPAC deal
Pharmaphorum
Medtech
SPAC
HDL Therapeutics
NASDAQ
atherosclerotic plaques
Flag link:
HIV cell therapy startup Addimmune heads to Wall Street via blank-check merger
HIV cell therapy startup Addimmune heads to Wall Street via blank-check merger
BioPharma Dive
Addimmune
HIV
SPAC
Flag link:
South Korean biotech group spies US SPAC as route to Nasdaq
South Korean biotech group spies US SPAC as route to Nasdaq
Fierce Biotech
OSR Holdings
South Korea
SPAC
NASDAQ
Flag link:
IPOs vs SPACs
IPOs vs SPACs
EP Vantage
IPOs
SPAC
Belite Bio
Cerevel Therapeutics
NewAmsterdam Pharma
Nuvectis Pharma
Oculis
Roivant Sciences
Flag link:
The slow death of the medtech SPAC deal
The slow death of the medtech SPAC deal
EP Vantage
devices
Medtech
SPAC
Seastar Medical
Docgo
Hims & Hers Health
Alpha Tau Medical
Prosomnus
Flag link:
Neurology startup merges with Wilbur Ross-backed SPAC
Neurology startup merges with Wilbur Ross-backed SPAC
BioPharma Dive
Aprinoia Therapeutics
Wilbur Ross
SPAC
Alzheimer's disease
Flag link:
Cancer-focused Liminatus sets out to test SPAC waters
Cancer-focused Liminatus sets out to test SPAC waters
Fierce Biotech
Liminatus Pharma
SPAC
Flag link:
Biotech startup Ocean pivots from IPO to SPAC merger
Biotech startup Ocean pivots from IPO to SPAC merger
BioPharma Dive
Ocean Biomedical
IPOs
SPAC
M&A
Aesther Healthcare Acquisition Corp
Flag link:
NewAmsterdam Pharma to Merge With SPAC Frazier Lifesciences
NewAmsterdam Pharma to Merge With SPAC Frazier Lifesciences
Marketwatch
NewAmsterdam Pharma
M&A
SPAC
Frazier Lifesciences
Flag link:
Four months after first intranasal flunks influenza test, Revelation's second-gen asset misses on efficacy
Four months after first intranasal flunks influenza test, Revelation's second-gen asset misses on efficacy
Endpoints
Revlation Biosciences
SPAC
clinical trials
Flu
Flag link:
SPAC merger called off as company connected to ex-Purdue CEO decides to remain private
SPAC merger called off as company connected to ex-Purdue CEO decides to remain private
Endpoints
Blade Therapeutics
Purdue Pharma
SPAC
M&A
Flag link:
Bristol Myers triples-down on Immatics, bringing deal to $4.2B total biobucks
Bristol Myers triples-down on Immatics, bringing deal to $4.2B total biobucks
Fierce Biotech
Bristol Myers Squibb
Immatics
SPAC
immunotherapy
drug discovery
biobucks
Flag link:
Ex-Sanofi CEO backs first European biomanufacturing SPAC
Ex-Sanofi CEO backs first European biomanufacturing SPAC
Pharmaforum
Sanofi
Gerard le Fur
SPAC
Europe
Flag link:
A medtech company's SPAC merger falls flat, missing on nine-figure valuation
A medtech company's SPAC merger falls flat, missing on nine-figure valuation
Endpoints
Medtech
SPAC
Accelus
Integrity Impants
Flag link:
Akili plays the Spac game for $1bn
Akili plays the Spac game for $1bn
EP Vantage
devices
Medtech
SPAC
Akili Interactive
Flag link:
Psychedelics biotech set to go public via SPAC — pushing IV form of psilocybin into PhI
Psychedelics biotech set to go public via SPAC — pushing IV form of psilocybin into PhI
Endpoints
Eleusis
SPAC
psychedelic drugs
Flag link:
Sema4 Looks to M&A After Successful SPAC
Sema4 Looks to M&A After Successful SPAC
Medical Devices and Diagnostics Industry
Sema4
OPKO Health
GeneDx
M&A
SPAC
Flag link:
Small biotech chaired by ex-Purdue CEO Mark Timney jumps into the SPAC lane
Small biotech chaired by ex-Purdue CEO Mark Timney jumps into the SPAC lane
Endpoints
Mark Timney
SPAC
Blade Therapeutics
Purdue Pharma
Biotech Acquisition Company
Flag link:
23andMe Stock Could Be a Big Winner If This 1 Thing Happens
23andMe Stock Could Be a Big Winner If This 1 Thing Happens
Motley Fool
23andMe
SPAC
diagnostics
Flag link:

Pages